Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

Is it safe?
About the author: 

Muraglitazar has been given the green light by America's drugs regulator, the Food and Drug Administration (FDA)

Muraglitazar has been given the green light by America's drugs regulator, the Food and Drug Administration (FDA). Its special advisory committee looked at the safety record, together with data from trials, and recommended its approval, which was duly given last October.

However, when a research team from Cleveland Clinic Foundation analysed the exact same data reviewed by the FDA advisory committee, they concluded that the drug is highly dangerous. Of the 2374 patients who were involved in testing the drug, 35 either died, or suffered a heart attack or stroke, and another 50 experienced either a TIA (transient ischaemic attack, a form of stroke), or chronic heart failure.

On that basis, the drug should never have been approved, the research team concluded. So how did it happen? One difference was that the pharmaceutical company that makes the drug made the presentation to the safety committee, whereas the Cleveland research team just looked at the raw data. The drug company also included a large group of people, taking minimal doses of the drug, who did not suffer any adverse reactions. Inclusion of these subjects diluted the figures, making a seemingly large problem appear almost insignificant.

In addition to the life-threatening reactions, the drug also caused major weight gain, and increased the risk of oedema (swelling due to water retention) by 10 per cent.

The drug's manufacturer has agreed to undertake a five-year safety trial involving 15,000 patients but, in the meantime, the drug will continue to be freely available on prescription (JAMA, 2005; 294: 2581-6, 2633-5).


You may also be interested in...

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved